Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study.

ABSTRACT:

Introduction

Patients with rheumatoid arthritis (RA) who are treated with adalimumab (ADA) are offered a proprietary patient support program (PSP, AbbVie Care^®). The main objective of this study was to examine the effectiveness of ADA on RA treatment course over time in the context of PSP utilization.

Methods

PASSION was a 78-week post-marketing observational study of RA patients with an insufficient response to ≥1 DMARD newly initiating ADA in routine clinical care that was conducted in Europe, Israel, Mexico, Puerto Rico, and Australia. One prior biologic DMARD was allowed. The primary endpoint was percentage of patients achieving the minimal clinically important difference (MCID; improvement of ≥0.22 compared to baseline) in Health Assessment Questionnaire (HAQ

SUBMITTER: Van den Bosch F 

PROVIDER: S-EPMC5443730 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature